)
)
)
Neurizon Therapeutics Ltd.
Neurizon Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies that target the underlying pathology of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease and Frontotemporal Dementia.
Our lead program, NUZ-001, is a first-in-class oral therapy designed to address core mechanisms of neurodegeneration, including TDP-43 protein aggregation and impaired autophagy. Because TDP-43 pathology is present in more than 95% of ALS cases and implicated across multiple neurodegenerative conditions, NUZ-001 has the potential to serve as a multi-indication platform therapy.
NUZ-001 has completed Phase 1 and OLE studies, demonstrating a favourable safety and tolerability profile with encouraging efficacy signals. The program is now preparing for inclusion in the Phase 2/3 HEALEY ALS Platform Trial, an established registration-level framework offering an accelerated and capital-efficient path to potential approval.
Address
MelbourneVictoria
Australia
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)